STOCK TITAN

Xeris Biopharma Holdings, Inc. - XERS STOCK NEWS

Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.

Xeris Biopharma Holdings, Inc. (Symbol: XERS) is a pioneering biopharmaceutical company committed to developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company's mission is to revolutionize patient care by creating ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices.

Xeris has successfully brought three groundbreaking products to market:

  • Gvoke: A ready-to-use liquid glucagon designed to treat severe hypoglycemia, providing a critical solution for diabetic patients.
  • Keveyis: The first FDA-approved therapy for primary periodic paralysis, offering relief for those suffering from this rare genetic disorder.
  • Recorlev: Approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome, addressing a previously unmet need in this patient population.

In addition to these commercial successes, Xeris continues to innovate with a robust pipeline of development programs. Utilizing its proprietary formulation technologies, XeriSol and XeriJect, the company aims to bring new therapies to market that ease the administration and increase the efficacy of injectable treatments.

Financially, Xeris Biopharma Holdings has shown significant growth and resilience in a competitive market. Their strategic partnerships and collaborations further bolster their developmental and commercial capabilities, ensuring a steady pipeline of innovative products aimed at improving patient outcomes.

Recent achievements and ongoing projects underline Xeris' commitment to enhancing the quality of life for millions of patients globally. Keep up with the latest updates and news about Xeris Biopharma Holdings, Inc. to stay informed about their ongoing advancements and performance in the biopharmaceutical industry.

Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference. CEO Paul R. Edick to provide an overview on February 13, 2024, at 10:00 am Eastern Time. Interested individuals can access the presentation on the investor relations page of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab using Xeris’ XeriJect® technology in Thyroid Eye Disease (TED). The agreement includes potential payments of $75 million in development and regulatory milestones, plus sales-based milestones, and escalating single-digit royalties based on future sales of TEPEZZA using the XeriJect technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.18%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) announced the grant of 130,000 restricted stock units to 18 new employees under its Inducement Equity Plan. The units will vest over three years and are subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
none
Rhea-AI Summary
Company XYZ (XYZ) anticipates achieving cashflow positivity in Q4, with total revenue expected to reach the upper end of the $160M-$165M range. The company also projects to end 2023 with over $72M in cash, cash equivalents, and short-term investments, surpassing its initial guidance of $65M-$70M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) achieved record revenue of $48.3M, a 27% increase from prior quarter and a 63% increase from same period prior year. Tightens full-year 2023 revenue guidance to $160M-$165M. Ended Q3 with $66.0M in cash, cash equivalents and short-term investments. Successfully extended maturity of 2025 Convertible Senior Notes to 2028. Formulated the prespecified target product profile of the XeriJect™ formulation of TEPEZZA®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.59%
Tags
Rhea-AI Summary
Xeris Biopharma Raises 2023 Financial Guidance and Receives $6 Million Milestone Payment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.25%
Tags
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. announces exchange agreements for convertible notes, providing financial flexibility and extending maturity date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences

FAQ

What is the current stock price of Xeris Biopharma Holdings (XERS)?

The current stock price of Xeris Biopharma Holdings (XERS) is $3.49 as of December 20, 2024.

What is the market cap of Xeris Biopharma Holdings (XERS)?

The market cap of Xeris Biopharma Holdings (XERS) is approximately 527.7M.

What does Xeris Biopharma Holdings, Inc. specialize in?

Xeris focuses on developing and commercializing innovative therapies in endocrinology, neurology, and gastroenterology.

What are the main products of Xeris Biopharma?

Xeris' main products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous hypercortisolemia in Cushing's Syndrome.

What is Gvoke used for?

Gvoke is a ready-to-use liquid glucagon designed to treat severe hypoglycemia in diabetic patients.

What makes Xeris' therapies unique?

Xeris' therapies are unique due to their ultra-low volume, ready-to-use formulations delivered through patient-friendly injectable devices.

What proprietary technologies does Xeris use?

Xeris uses proprietary formulation technologies such as XeriSol and XeriJect to enhance the administration and efficacy of injectable treatments.

How many products has Xeris successfully commercialized?

Xeris has three commercially available products: Gvoke, Keveyis, and Recorlev.

What is Keveyis used for?

Keveyis is the first FDA-approved therapy for primary periodic paralysis, a rare genetic disorder.

What is Recorlev approved to treat?

Recorlev is approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

What are XeriSol and XeriJect?

XeriSol and XeriJect are Xeris' proprietary formulation technologies used to develop advanced injectable therapies.

Where can I find the latest news about Xeris Biopharma Holdings?

You can find the latest news about Xeris Biopharma Holdings on their official website and stock market news platforms like StockTitan.

Xeris Biopharma Holdings, Inc.

Nasdaq:XERS

XERS Rankings

XERS Stock Data

527.75M
141.54M
3.92%
43.81%
6.81%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO